State Street SPDR S&P Biotech ETF XBI
151.98 USD +3.58 (+2.41%)
Nov 6, 2026, 1:14 PM EST
147.56 Day range 152.10
106.30 52-week range 169.89
- YTD
- +24.64%
- 1 year
- +39.06%
- Market cap
- 7.76B
- YTD return
- +24.64%
- 1-year return
- +39.06%
- Volume
- 6.17M
- Avg volume
- 9.05M
- Open
- 148.39
- Previous close
- 148.40
- Day's range
- 147.56 – 152.10
- 52-week range
- 106.30 – 169.89
1Y +42.40 (+38.91%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 156.14
- 200-day average
- 141.93
Next earnings
Consensus EPS estimate 0.00.
About State Street SPDR S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
News
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge 
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs 
Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today 
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach 
Economy Grows 63% in Six Years, 30-Year Treasury Lost Almost As Much 
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets 
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back 
What's Going On With Novavax Stock? 
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs 
Novavax Stock Climbs Monday: What's Going On?
Your note
Sign in to keep a note on XBI — it syncs with the Stock Master app.